NBO Pharma See The Immediate Benefits of An Integrated Approach to Intranasal Product Development with The Aptar Pharma Family of Services

Dry powder inhaler, Nanopharm, OINDPs

17 Aug 2026

NBO Pharma See The Immediate Benefits of An Integrated Approach to Intranasal Product Development with The Aptar Pharma Family of Services

Download the NBO Pharma See The Immediate Benefits of An Integrated Approach to Intranasal Product Development with The Aptar Pharma Family of Services

Articles

Balancing Creativity with Compliance: Meet Kirsten Searle, Manager of Pharma Development

Discover how Kirsten Searle is enhancing project management excellence at Nanopharm. Hear about her philosophy on balancing pragmatic process with scientific innovation in a fast-paced CRO environment.

July 6, 2026 No Comments

Articles

Inhaled Generic Bioequivalence Modeling Approaches

Learn how advanced in vitro and in silico modeling help generics companies overcome complex bioequivalence hurdles for orally inhaled drug products (OIDPs).

July 6, 2026 No Comments

Articles

First Reflections on RDD 2026: FDA Guidance Updates Highlight Progress for NGP pMDIs

Discover first reflections on RDD 2026 from Phoenix, Arizona, highlighting the impact of the research programme funded by FDA and exemplifying Nanopharm’s recognized scientific contributions to supporting the transition to next-generation propellant metered dose inhalers (pMDIs).

May 29, 2026 No Comments

About Us

Product Development

Analytical Services

In-Silico Modeling

Regulatory

Nasal

Inhalation

Inhaled Biologics

Generics & Lifecycle Management

Resources

17 Aug 2026

NBO Pharma See The Immediate Benefits of An Integrated Approach to Intranasal Product Development with The Aptar Pharma Family of Services

Related Posts

Balancing Creativity with Compliance: Meet Kirsten Searle, Manager of Pharma Development

Inhaled Generic Bioequivalence Modeling Approaches

First Reflections on RDD 2026: FDA Guidance Updates Highlight Progress for NGP pMDIs